OR WAIT null SECS
The companies will work together to produce enFuse, a patient-administered subcutaneous delivery device.
Device manufacturer Enable Injections, Inc. announced it has entered into a development agreement with Genentech for programs using Enable’s enFuse, an investigational wearable infusion device that allows patient-administered subcutaneous delivery of high-volume therapeutics. The collaboration has the potential for multiple molecule development programs incorporating long-term manufacturing and supply arrangements.
According to an Aug. 21, 2019 press release, the device is an on-body drug delivery platform with a drug transfer system compatible with standard syringes or vial container formats. It is designed for subcutaneous administration of large volumes ranging up to 50 mL and has the potential to provide patients and caregivers with an alternative delivery method for subcutaneous administration of parenteral therapies outside of a clinical setting.
“Enable Injections is pleased to partner with Genentech in its focus on delivering patient-focused solutions,” said Michael D. Hooven, Enable Injections founder, president, and CEO, in the press release. “With the enFuse paired to deliver selected subcutaneous therapeutics, it can potentially benefit patients worldwide.”
Source: Enable Injections, Inc.